NextBiomedical begins US pivotal trial for Nexsphere-F knee pain device

NextBiomedical this week announced it enrolled the first patient in its U.S. pivotal clinical trial evaluating its Nexsphere-F, a fast-resorbable microsphere for embolization treatment of musculoskeletal pain.

The multicenter study, called RESORB (Randomized Controlled Study Evaluating Genicular Artery Embolization Against Intra-Articular Corticosteroid Knee Injection for Osteoarthritic Knee Pain), will enroll about 126 patients at more than 10 U.S. clinical sites. The trial compares genicular artery embolization (GAE) using Nexsphere-F to intra-articular corticosteroid injections, assessing safety and efficacy for patients with knee osteoarthritis.

See full article: https://www.massdevice.com/nextbiomedical-begins-us-pivotal-trial-for-nexsphere-f-knee-pain-device/